Cannabis stocks faced a precarious summer last year, but one analyst has noted that “equity markets (are) rebounding,” causing an upswing across the sector — including in Australia.

In a note sent to investors on January 22, Cameron Bell, an analyst with boutique bank Canaccord Genuity Australia, said investor confidence in the Australian cannabis market has been renewed due to an exceptionally strong recent performance from the global cannabis space.


Canaccord’s own Australian Cannabis Index has risen 34 percent over the last month, Bell said, bouncing back from the hit of over 50 percent that it took in 2019.

 

Gold Outlook 2021!

   
Gold Price Outlook, Top Stocks and More! Download today!

“The strength has been partially led by investor sentiment in offshore markets, as some key concerns have eased while expectations for demand growth remain very high and access to funding improves.”

Bell also attributed more reasonable valuations as an aid to rising share prices.

Some of the largest companies on Canaccord’s index by market cap, including EcoFibre (ASX:EOF), Elixinol Global (ASX:EXL,OTC Pink:ELLXF) and Cann Group (ASX:CAN,OTC Pink:CNGGF), have seen impressive growth in the last month.

EcoFibre is up almost 10 percent in the last month, while Elixinol and Cann Group have soared 68.9 percent and 114.7 percent, respectively, in the same span of time.

Meanwhile, Bell said patient applications through the Therapeutics Goods Association’s (TGA) Special Access Scheme-B (SAS-B) pathway were on the rise in December.

Approvals for patients increased to 3,685 application authorizations that month, up 8 percent from the 3,404 confirmations in November.

December’s numbers are also almost seven times larger year-over-year than the 490 approvals issued in December 2018, indicating a rapid rise in patient adoption for these items.

By the end of 2019, the TGA had approved over 28,000 patients throughout the year. This figure exceeded Canaccord’s expectation of 25,000 approvals, reported in a previous Australian cannabis update released in November.

Ninety percent of total SAS-B approvals have happened in the last year, Bell noted.

If growth continues at the current rate, the total number of approvals is expected to grow to 72,000 by the end of calendar 2020.

The analyst noted that there’s been an interesting shift away from the Authorised Prescribers path, which gives medical practitioners in Australia the ability to prescribe unapproved therapeutic goods, like cannabis, directly to eligible patients.

According to the TGA, there were 22 authorised prescribers in Australia at the end of December, a steep drop from the 60 reported at the end of July, Bell wrote.

Don’t forget to follow us @INN_Australia for real-time news updates!

Securities Disclosure: I, Danielle Edwards, hold no direct investment interest in any company mentioned in this article.

  Life Science and Healthcare Investing in 2020 report cover

Coronavirus:An Overview for Investors

 
COVID-19 continues to impact world markets. Get INN’s overview of coronavirus investing.
 

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NASDAQ: CGC) will release its financial results for the third quarter fiscal 2021 ended December 31, 2020 before financial markets open on February 9, 2021.

Keep reading... Show less

NYSE | TSX: ACB

Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the closing of its previously announced bought deal public offering (the “Offering”) of units of the Company (the “Units”) for total gross proceeds of US$137,940,000 . The Company sold 13,200,000 Units at a price of US$10.45 per Unit, including 1,200,000 Units sold pursuant to the exercise in full of the underwriters’ over-allotment option.

Keep reading... Show less

Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE | TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the closing of its previously announced bought deal public offering (the “Offering”) of units of the Company (the “Units”) for total gross proceeds of US$137,940,000. The Company sold 13,200,000 Units at a price of US$10.45 per Unit, including 1,200,000 Units sold pursuant to the exercise in full of the underwriters’ over-allotment option.

Each Unit is comprised of one common share of the Company (a “Common Share”) and one half of one common share purchase warrant of the Company (each full common share purchase warrant, a “Warrant”). Each Warrant is exercisable to acquire one common share of the Company (a “Warrant Share”) for a period of 36 months following the closing date of the Offering at an exercise price of US$12.60 per Warrant Share, subject to adjustment in certain events.

Keep reading... Show less

AMP German Cannabis Group Inc. (” AMP “) (CSE: XCX ), ( Frankfurt : C4T ) (ISIN: CA00176G1028) and Aphria Inc.’s (” Aphria “) (TSX: APHA ) (NASDAQ: APHA) wholly-owned German subsidiary, CC Pharma GmbH (” CC Pharma “), have entered into a strategic agreement (the ” Co-Promotion Agreement “) covering joint marketing of sales for Aphria brand medical cannabis products for the German market.

The Co-Promotion Agreement is a collaboration contract between AMP and CC Pharma to sell the Aphria medical cannabis brand in Germany . In addition, AMP will organize with the support of CC Pharma, “information events” in Germany to market Aphria branded products to doctors and pharmacists.

Keep reading... Show less

HempFusion Wellness Inc. ( TSX:CBD.U ) ( FWB:8OO ) (“ HempFusion ” or the “ Company ”) is pleased to announce that it has been included in two leading cannabis & hemp-derived CBD focused exchange-traded funds (“ ETFs ”), AdvisorShares Pure US Cannabis ETF ( NYSE:MSOS ) and AdvisorShares Pure Cannabis ETF ( NYSE:YOLO ).

AdvisorShares is a leading sponsor of actively managed ETFs. Pure US Cannabis ETF (MSOS) is the only US-listed ETF dedicated solely to US cannabis exposure, with over US$616,000,000 in assets under management (“ AUM ”). Pure Cannabis ETF (YOLO) was the first US-based actively managed ETF focused on the global cannabis industry. YOLO and MSOS endeavor to achieve long-term capital growth by investing in some of the largest foreign and domestic cannabis and hemp-derived CBD companies. The two AdvisorShares ETFs have a combined AUM of over US$880,000,000 as of January 22, 2021.

Keep reading... Show less